Dr Reddy's Laboratories, based in India, has introduced alfuzosin hydrochloride, indicated for treatment of signs and symptoms of benign prostatic hyperplasia (BPH).
The drug has been introduced under the brand name Alfoo and is available in extended-release tablets of 10-mg dosage.
The product is being launched throughout India and will be available in more than 5,700 retail counters. Future plans for Alfoo include complete patient information program on prostate care using multimedia and print material.
BPH is the most common non-neoplastic disorder of aging men. The prevalence
of BPH increases from 8 percent in men between 31 and 40 years of age to 50
percent in men between 51 and 60 years of age.
